 

Chemed Corporation reported third quarter 2020 operating results that showed sequential improvement starting in May 2020, with admissions increasing 4.7% and an average daily census declining two-tenths of 1 percentage point. The federal government's support of hospice operations through regulations and flexibility in caring for patients has helped mitigate the severe initial disruption in patient referral and admission patterns. Roto-Rooter services demand has shown significant improvement, with unit-for-unit commercial revenue declining 11.6% in the third quarter when compared to the prior year quarter, an improvement from the 29.1% decline in the second quarter 2020 commercial revenue. VITAS' full year 2020 adjusted EBITDA margin prior to Medicare Cap is estimated to be 21%, and Roto-Rooter is forecasted to achieve full year 2020 revenue growth of 12.5% to 13%. Chemed's full year 2020 adjusted earnings per diluted share, excluding non-cash expense for stock options, tax benefits for stock options, costs related to litigation and other discrete items, is estimated to be in the range of $18 to $18.15. The company is confident in its ability to support its team members and deliver care safely by prioritizing